ClinicalTrials.gg
RecruitingNCT07130604Updated Dec 9, 2025

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of D-2570 and Placebo in Plaque Psoriasis, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by InventisBio Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
40th of 182
390 · median 171
Started
2025
with 35 others
Phase 3
58 of 206
16 open now
Primary completion
2027-07
later than 45 of 65 live
Registered
168th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 40th largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 58 in phase 3, reaches primary completion later than 45 of the 65 other live ones, and was the 168th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis, with a total of 390 subjects planned to be enrolled.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;
  2. Plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing ;
  3. During the screening period and before taking the drug for the first time, psoriatic surface area (BSA) ≥10%, PGA score ≥ 3, PASI score ≥ 12;
  4. Hematology, Blood chemistry and Urinalysis examination were basically normal.

Exclusion criteria

Exclusion Criteria:

  1. Erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis;
  2. Have other skin lesions that affect the evaluation of treatment outcomes, such as eczema;
  3. History of herpes zoster/herpes simplex, or presence of herpes zoster/herpes simplex infection during the screening period;
  4. Have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection;
  5. Other conditions that the investigator considers inappropriate for participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    D-2570 group1

    Drug: D-2570

  • Experimental
    D-2570 group2

    Drug: D-2570

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • DrugD-2570

    Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.

  • DrugPlacebo

    Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.

06

What researchers measure

Primary outcomes

  1. The percentage of subjects with at least 90% improvement in PASI

    The percentage of subjects with at least 90% improvement in PASI from baseline at week 16 of treatment.

    Time frame: Day 1-Day 112

Secondary outcomes

  1. Percentage of subjects with a PGA

    Percentage of subjects with a PGA score of 0 or 1 and ≥2 points from baseline at week 16 of treatment.

    Time frame: Day 1-Day 112

  2. The percentage of subjects with at least 75% improvement in PASI

    The percentage of subjects with at least 75% improvement in PASI from baseline at each visit.

    Time frame: Day1-Day365

  3. The percentage of subjects with at least 90% improvement in PASI

    The percentage of subjects with at least 90% improvement in PASI from baseline at each visit.

    Time frame: Day1-Day365

  4. The percentage of subjects with at least 100% improvement in PASI

    The percentage of subjects with at least 100% improvement in PASI from baseline at each visit.

    Time frame: Day1-Day365

  5. The percentage of subjects with improvement in PASI

    The percentage of subjects with improvement in PASI from baseline at each visit.

    Time frame: Day1-Day365

  6. Percentage of subjects with a PGA

    Percentage of subjects with a PGA score of 0 or 1 and ≥2 points from baseline at each visit.

    Time frame: Day1-Day365

  7. The percentage of subjects with at least 90% improvement in PASI

    The percentage of subjects with at least 90% improvement in PASI from baseline at week 16 of treatment and maintained response at Week 52.

    Time frame: Day1-Day365

  8. Percentage of subjects with a PGA score of 0 or 1 and ≥2 points from baseline

    Percentage of subjects with a PGA score of 0 or 1 and ≥2 points from baseline at week 16 of treatment and maintained response at Week 52.

    Time frame: Day1-Day365

  9. Percentage of subjects with baseline ss-PGA score ≥3

    Percentage of subjects with baseline ss-PGA score ≥3 who achieved ss-PGA 0 or 1 at Week 16 of treatment.

    Time frame: Day 1-Day 112

  10. Percentage of subjects with baseline PGA-F score ≥3

    Percentage of subjects with baseline PGA-F score ≥3 who achieved ss-PGA 0 or 1 at Week 16 of treatment.

    Time frame: Day 1-Day 112

  11. Percentage of subjects with baseline pp-PGA score ≥3

    Percentage of subjects with baseline pp-PGA score ≥3 who achieved ss-PGA 0 or 1 at Week 16 of treatment.

    Time frame: Day 1-Day 112

  12. Percentage of subjects with baseline DLQI score ≥2

    Percentage of subjects with baseline DLQI score ≥2 who achieved DLQI 0 or 1 at Week 16 of treatment.

    Time frame: Day 1-Day 112

  13. The main PK parameters -Time to maximum measured plasma concentration -Tmax Population pharmacokinetic characteristics of D-2570

    The main PK parameters -Time to maximum measured plasma concentration -Tmax

    Time frame: Day1-Day365

  14. The main PK parameters#Area under the plasma concentration versus time curve-AUC

    The main PK parameters#Area under the plasma concentration versus time curve-AUC

    Time frame: Day1-Day365

  15. The main PK parameters-Vz/F (apparent volume of distribution)

    The main PK parameters-Vz/F (apparent volume of distribution)

    Time frame: Day1-Day365

  16. The main PK parameters Half-life -t1/2

    The main PK parameters Half-life -t1/2

    Time frame: Day1-Day365

  17. The main PK parameters-CL/F (apparent clearance)

    The main PK parameters-CL/F (apparent clearance)

    Time frame: Day1-Day365

  18. Weight and height will be combined to report BMI in kg/m^2

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: Day1-Day365

  19. Incidence and severity of AEs based on NCI CTCAE V5.0

    Incidence and severity of AEs based on NCI CTCAE V5.0

    Time frame: Day1-Day365

  20. Incidence and severity of TEAEs based on NCI CTCAE V5.0

    Incidence and severity of TEAEs based on NCI CTCAE V5.0

    Time frame: Day1-Day365

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 22 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 19, 2025
StartActual
Sep 18, 2025
Primary completionEst.
Jul 28, 2027
CompletionEst.
Jul 28, 2027
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07130604
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 18, 2025
Primary completion
Jul 28, 2027 (estimated)
Completion
Jul 28, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

Nan Tang
Contact
nan.tang@inventisbio.com
021-50663661
Jianzhong Zhang
principal investigator · Study Official is required by the WHO and ICMJE.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-2570

Start the discussion